BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 26483549)

  • 1. IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1).
    Chen Z; Su L; Xu Q; Katz J; Michalek SM; Fan M; Feng X; Zhang P
    J Biol Chem; 2015 Dec; 290(50):30163-74. PubMed ID: 26483549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR2-dependent modulation of osteoclastogenesis by Porphyromonas gingivalis through differential induction of NFATc1 and NF-kappaB.
    Zhang P; Liu J; Xu Q; Harber G; Feng X; Michalek SM; Katz J
    J Biol Chem; 2011 Jul; 286(27):24159-69. PubMed ID: 21566133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts.
    Yang S; Takahashi N; Yamashita T; Sato N; Takahashi M; Mogi M; Uematsu T; Kobayashi Y; Nakamichi Y; Takeda K; Akira S; Takada H; Udagawa N; Furusawa K
    J Immunol; 2005 Aug; 175(3):1956-64. PubMed ID: 16034140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agrimophol suppresses RANKL-mediated osteoclastogenesis through Blimp1-Bcl6 axis and prevents inflammatory bone loss in mice.
    Cao J; Wang S; Wei C; Lin H; Zhang C; Gao Y; Xu Z; Cheng Z; Sun WC; Wang HB
    Int Immunopharmacol; 2021 Jan; 90():107137. PubMed ID: 33199235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
    Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
    J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
    Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
    J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation.
    Nishikawa K; Nakashima T; Hayashi M; Fukunaga T; Kato S; Kodama T; Takahashi S; Calame K; Takayanagi H
    Proc Natl Acad Sci U S A; 2010 Feb; 107(7):3117-22. PubMed ID: 20133620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.
    Kalliolias GD; Zhao B; Triantafyllopoulou A; Park-Min KH; Ivashkiv LB
    Arthritis Rheum; 2010 Feb; 62(2):402-13. PubMed ID: 20112358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Porphyromonas gingivalis Stimulates Bone Resorption by Enhancing RANKL (Receptor Activator of NF-κB Ligand) through Activation of Toll-like Receptor 2 in Osteoblasts.
    Kassem A; Henning P; Lundberg P; Souza PP; Lindholm C; Lerner UH
    J Biol Chem; 2015 Aug; 290(33):20147-58. PubMed ID: 26085099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unkeito Suppresses RANKL-Mediated Osteoclastogenesis via the Blimp1-Bcl6 and NF-κB Signaling Pathways and Enhancing Osteoclast Apoptosis.
    Fang K; Murakami Y; Kanda S; Shimono T; Dang AT; Ono M; Nishiyama T
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis.
    Miyauchi Y; Ninomiya K; Miyamoto H; Sakamoto A; Iwasaki R; Hoshi H; Miyamoto K; Hao W; Yoshida S; Morioka H; Chiba K; Kato S; Tokuhisa T; Saitou M; Toyama Y; Suda T; Miyamoto T
    J Exp Med; 2010 Apr; 207(4):751-62. PubMed ID: 20368579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
    Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha.
    Sato N; Takahashi N; Suda K; Nakamura M; Yamaki M; Ninomiya T; Kobayashi Y; Takada H; Shibata K; Yamamoto M; Takeda K; Akira S; Noguchi T; Udagawa N
    J Exp Med; 2004 Sep; 200(5):601-11. PubMed ID: 15353553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of the myeloid differentiation factor 88 (MyD88) on RANKL, OPG, and nod expressions induced by TLR and IL-1R signaling in bone marrow stromal cells.
    Leite FR; de Aquino SG; Guimarães MR; Cirelli JA; Zamboni DS; Silva JS; Junior CR
    Inflammation; 2015 Feb; 38(1):1-8. PubMed ID: 25125146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis.
    Cheng J; Liu J; Shi Z; Xu D; Luo S; Siegal GP; Feng X; Wei S
    J Cell Biochem; 2011 Nov; 112(11):3385-92. PubMed ID: 21751242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
    Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
    Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-33 inhibits RANKL-induced osteoclast formation through the regulation of Blimp-1 and IRF-8 expression.
    Kiyomiya H; Ariyoshi W; Okinaga T; Kaneuji T; Mitsugi S; Sakurai T; Habu M; Yoshioka I; Tominaga K; Nishihara T
    Biochem Biophys Res Commun; 2015 May; 460(2):320-6. PubMed ID: 25795135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
    Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.